Lowenstein represented ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases, in its agreement with Larkspur Health Acquisition Corp. (NASDAQ: LSPR), a blank-check special purpose acquisition company (SPAC), to enter into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa's renal and inflammasome product candidate pipelines.

The combined company will have an estimated pro forma enterprise valuation of approximately $108.92 million.

The Lowenstein deal team included Michael J. Lerner, Jared Kelly, Steven M. Skolnick, Kate Basmagian, Daniel C. Porco, James Assmann, Chelmie Ulysse, and Ricardo Gray.

About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.

Contact(s):
Penny Paul
Sr. Manager, Marketing Communications
Lowenstein Sandler LLP
(973) 597-2592
ppaul@lowenstein.com